07:09 AM EDT, 09/16/2024 (MT Newswires) -- Pfizer ( PFE ) said on Saturday that its experimental drug, ponsegromab, for treating cancer cachexia met the main goal in a phase 2 study.

The study showed that those who received ponsegromab showed significant improvement in body weight, muscle mass, quality of life, and physical function compared to placebo, with no significant adverse effects observed.

Based on the positive results, the company said it is in talks with regulators to begin late-stage, registration-enabling studies in 2025.

Price: 29.40, Change: +0.13, Percent Change: +0.44